Chugai Pharmaceutical Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 14 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
9.3M | +0.01% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
8.3M | +0.27% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
5.9M | +2.67% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
5.6M | -4.54% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
4.6M | +1.13% | |
|
NEW PERSPECTIVE FUND
|
4.2M | -38.60% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
5.4K | -5.36% |
Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥250 | +155.1% |
| 2024 | ¥98 | +22.5% |
| 2023 | ¥80 | +2.6% |
| 2022 | ¥78 | +2.6% |
| 2021 | ¥76 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥999,758M | ¥1,259,726M | ¥1,111,367M | ¥1,170,611M |
| Gross Profit | ¥661,612M | ¥783,475M | ¥698,061M | ¥831,201M |
| Operating Income | ¥421,897M | ¥533,308M | ¥439,174M | ¥542,002M |
| Pretax Income | ¥419,433M | ¥531,227M | ¥443,848M | ¥542,002M |
| Net Income | ¥302,995M | ¥374,429M | ¥325,472M | ¥387,317M |
| EPS | ¥184.17 | ¥227.57 | ¥197.80 | ¥235.36 |
| Operating Margin | 42.20% | 42.34% | 39.52% | 46.30% |
| Balance Sheet | ||||
| Total Assets | ¥1,538,694M | ¥1,869,758M | ¥1,932,547M | ¥2,208,373M |
| Total Equity | ¥1,188,017M | ¥1,424,387M | ¥1,625,580M | ¥1,901,499M |
| Total Liabilities | ¥350,677M | ¥445,371M | ¥306,967M | ¥306,874M |
| Cash | ¥267,753M | ¥222,169M | ¥458,674M | ¥540,202M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 77.21% | 76.18% | 84.12% | 86.10% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥279,626M | ¥243,582M | ¥409,925M | ¥447,600M |
| Investing CF | -¥118,927M | -¥145,465M | -¥37,290M | -¥227,365M |
| Financing CF | -¥107,408M | -¥145,641M | -¥139,331M | -¥141,006M |
| Free CF | ¥206,760M | ¥172,343M | ¥335,667M | ¥392,701M |
| Efficiency | ||||
| ROE | 25.50% | 26.29% | 20.02% | 20.37% |
| ROA | 19.69% | 20.03% | 16.84% | 17.54% |
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥8,764
Rating Score: 2.14 (Based on 14 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
